Zai Lab Operating Income 2016-2022 | ZLAB

Zai Lab operating income from 2016 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Zai Lab Annual Operating Income
(Millions of US $)
2021 $-700
2020 $-302
2019 $-203
2018 $-142
2017 $-51
2016 $-39
2015 $-16
Zai Lab Quarterly Operating Income
(Millions of US $)
2022-03-31 $-80
2021-12-31 $-219
2021-09-30 $-83
2021-06-30 $-171
2021-03-31 $-227
2020-12-31 $-95
2020-09-30 $-76
2020-06-30
2020-03-31 $-46
2019-12-31
2019-09-30
2019-06-30
2018-12-31
2017-12-31
2017-06-30
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.334B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00